STOCK TITAN

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

GRAIL (Nasdaq: GRAL) has announced the granting of equity awards to 46 newly hired non-executive employees. The awards consist of restricted stock units (RSUs) totaling 115,093 shares of GRAIL's common stock. These inducement grants were made under GRAIL's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over approximately four years, with 25% vesting on November 30, 2025, and the remaining portions vesting annually thereafter, contingent on continued employment with GRAIL or its subsidiaries.

GRAIL (Nasdaq: GRAL) ha annunciato l'assegnazione di premi in azioni a 46 nuovi dipendenti non esecutivi. I premi consistono in unità azionarie ristrette (RSU) per un totale di 115.093 azioni delle azioni ordinarie di GRAIL. Questi premi di indennizzo sono stati concessi nell'ambito del Piano di Incentivi Azionari di Indennizzo di GRAIL, in conformità con la Regola 5635(c)(4) della Nasdaq.

Le RSU maturaanno in un periodo di circa quattro anni, con il 25% che matura il 30 novembre 2025, e le rimanenti porzioni che matureranno annualmente in seguito, subordinatamente alla continuazione del rapporto di lavoro con GRAIL o le sue filiali.

GRAIL (Nasdaq: GRAL) ha anunciado la concesión de premios en acciones a 46 nuevos empleados no ejecutivos. Los premios consisten en unidades de acciones restringidas (RSUs) que totalizan 115,093 acciones de las acciones comunes de GRAIL. Estos premios de inducción se otorgaron bajo el Plan de Incentivos de Inducción de Capital de GRAIL, en cumplimiento con la Regla de Cotización 5635(c)(4) de Nasdaq.

Las RSUs se consolidarán en un período de aproximadamente cuatro años, con el 25% consolidándose el 30 de noviembre de 2025, y las porciones restantes consolidándose anualmente a partir de entonces, condicionadas a la permanencia en el empleo con GRAIL o sus subsidiarias.

GRAIL (Nasdaq: GRAL)은 46명의 비전문 직원에게 주식 보상을 부여했다고 발표했습니다. 이 보상은 GRAIL의 보통주 115,093주에 해당하는 제한 주식 단위(RSU)로 구성됩니다. 이 유인 보상은 Nasdaq 상장 규정 5635(c)(4)에 따라 GRAIL의 유인 주식 인센티브 계획에 따라 이루어졌습니다.

RSU는 약 4년에 걸쳐 만기되며, 25%는 2025년 11월 30일에 만기되며, 이후 나머지 부분은 연례적으로 만기되며 GRAIL 또는 그 자회사의 계속된 고용에 따라 달라집니다.

GRAIL (Nasdaq: GRAL) a annoncé l'octroi de récompenses en actions à 46 nouveaux employés non dirigeants. Les récompenses consistent en des unités d'actions restreintes (RSU) totalisant 115 093 actions des actions ordinaires de GRAIL. Ces attributions incitatives ont été effectuées dans le cadre du Plan d'Incentives en Actions de GRAIL, conformément à la Règle de Cotation 5635(c)(4) de Nasdaq.

Les RSU vont se matérialiser sur une période d'environ quatre ans, avec 25 % se matérialisant le 30 novembre 2025, et les portions restantes se matérialiseront annuellement par la suite, sous réserve de la poursuite de l'emploi chez GRAIL ou de ses filiales.

GRAIL (Nasdaq: GRAL) hat die Gewährung von Aktienprämien an 46 neu eingestellte nicht-executive Mitarbeiter bekannt gegeben. Die Prämien bestehen aus eingeschränkten Aktieneinheiten (RSUs) in Höhe von 115.093 Aktien der Stammaktien von GRAIL. Diese Anreizgewährungen wurden im Rahmen von GRAILs Anreiz-Aktienplan gemäß der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.

Die RSUs werden über einen Zeitraum von etwa vier Jahren erworben, wobei 25% am 30. November 2025 fällig werden und die verbleibenden Anteile danach jährlich fällig werden, abhängig von der Fortdauer der Anstellung bei GRAIL oder deren Tochtergesellschaften.

Positive
  • Employee retention strategy implemented through equity-based compensation
  • Successful recruitment of 46 new employees indicating company growth
Negative
  • Potential shareholder dilution from issuance of 115,093 new shares

Insights

The RSU grants, while a standard practice for employee retention, represent a notable dilution of approximately 0.12% of GRAIL's outstanding shares. With a $632 million market cap, these equity awards have an estimated value of around $750,000 based on current share prices. The four-year vesting schedule is typical for the biotech industry, designed to retain talent while aligning employee interests with long-term company success. However, this news primarily relates to routine compensation matters and has minimal impact on the company's immediate financial outlook or stock performance.

MENLO PARK, Calif., Dec. 3, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 115,093 shares of GRAIL's common stock to 46 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting November 30, 2025, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302321454.html

SOURCE GRAIL, Inc.

FAQ

How many shares of GRAIL (GRAL) were granted as RSUs in December 2024?

GRAIL granted RSUs underlying 115,093 shares of common stock to newly hired employees.

What is the vesting schedule for GRAIL's (GRAL) December 2024 RSU grants?

The RSUs vest over four years, with 25% vesting on November 30, 2025, and annually thereafter.

How many new employees received RSU grants from GRAIL (GRAL) in December 2024?

46 newly hired non-executive employees received RSU grants.

GRAIL, Inc.

NASDAQ:GRAL

GRAL Rankings

GRAL Latest News

GRAL Stock Data

616.47M
28.98M
13.75%
67.1%
11.25%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
MENLO PARK